RA Capital Management, L.P. Increases Position in Contineum Therapeutics, Inc. to 4.0%

On May 15, 2026, RA Capital Management, L.P., along with Peter Kolchinsky and Rajeev Shah, filed an amended Schedule 13G (Amendment No. 2) regarding their holdings in Contineum Therapeutics, Inc. (CTNM). The filing reports that as of March 31, 2026, the reporting persons beneficially own 1,296,012 shares of Class A Common Stock, representing 4.0% of the company's outstanding shares. This reflects an increase from a previously reported 0.0% position. The shares are directly held by the RA Capital Healthcare Fund, L.P., with RA Capital Management serving as the investment adviser. Dr. Kolchinsky and Mr. Shah are the controlling persons of the general partner of RA Capital. The reporting persons have shared voting and dispositive power over the shares. The filing was made under Rule 13d-1(c), certifying that the acquisition was not intended to influence or change the control of the issuer. The percentage ownership is based on 32,673,536 shares outstanding as of February 27, 2026.